Effects of rotigotine on Parkinson's disease-related sleep disturbances

Bibliography

• Colosimo C, Morgante L, Antonini A, et al. Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol 2010;257:5-14
   PubMed Web of Science ®Google Scholar
• Khedr EM, El Fetoh NA, Khalifa H, et al. Prevalence of non motor features in a cohort of Parkinson's disease patients. Clin Neurol Neurosurg 2012;115:673-7
   PubMed Web of Science ®Google Scholar
• Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988;11:512-19
   PubMed Web of Science ®Google Scholar
• Comella CL. Sleep disorders in Parkinson's disease: an overview. Mov Disord 2007;22(Suppl 17):S367-73
   Google Scholar
• Zoccolella S, Savarese M, Lamberti P, et al. Sleep disorders and the natural history of Parkinson's disease: the contribution of epidemiological studies. Sleep Med Rev 2011;15:41-50
   PubMed Web of Science ®Google Scholar
• Oerlemans WG, de Weerd AW. The prevalence of sleep disorders in patients with Parkinson's disease. A self-reported, community-based survey. Sleep Med 2002;3:147-9
   PubMed Web of Science ®Google Scholar
• Iranzo de Riquer A, Bergareche A, Campos V. Sleep disorders in Parkinson disease. Neurologist 2011;17(6 Suppl 1):S38-42
   PubMedGoogle Scholar
• Videnovic A, Golombek D. Circadian and sleep disorders in Parkinson's disease. Exp Neurol 2012;243:45-56
   PubMed Web of Science ®Google Scholar
• Dhawan V, Healy DG, Pal S, Chaudhuri KR. Sleep-related problems of Parkinson's disease. Age Ageing 2006;35:220-8
   PubMed Web of Science ®Google Scholar
• Menza M, Dobkin RD, Marin H, Bienfait K. Sleep disturbances in Parkinson's disease. Mov Disord 2010;25(Suppl 1):S117-22
   PubMed Web of Science ®Google Scholar
• Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 1986;9:293-308
   PubMed Web of Science ®Google Scholar
• Montplaisir J, Gagnon JF, Fantini ML, et al. Polysomnographic diagnosis of idiopathic REM sleep behavior disorder. Mov Disord 2010;25:2044-51
   PubMed Web of Science ®Google Scholar
• Nielsen T, Svob C, Kuiken D. Dream-enacting behaviors in a normal population. Sleep 2009;32:1629-36
   PubMed Web of Science ®Google Scholar
• Comella CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology 1998;51:526-9
   PubMed Web of Science ®Google Scholar
• Vibha D, Shukla G, Goyal V, et al. RBD in Parkinson's disease: a clinical case control study from North India. Clin Neurol Neurosurg 2011;113:472-6
   PubMed Web of Science ®Google Scholar
• Claassen DO, Josephs KA, Ahlskog JE, et al. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010;75:494-9
   PubMed Web of Science ®Google Scholar
• Iranzo A, Valldeoriola F, Lomena F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2011;10:797-805
   PubMed Web of Science ®Google Scholar
• Stockner H, Iranzo A, Seppi K, et al. Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Mov Disord 2009;24:1906-9
   PubMed Web of Science ®Google Scholar
• Luppi PH, Clement O, Sapin E, et al. The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder. Sleep Med Rev 2010;15:153-63
   PubMed Web of Science ®Google Scholar
• Boeve BF, Silber MH, Saper CB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007;130:2770-88
   PubMed Web of Science ®Google Scholar
• Scherfler C, Frauscher B, Schocke M, et al. White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol 2011;69:400-7
   PubMed Web of Science ®Google Scholar
• Monti JM, Jantos H. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking. Prog Brain Res 2008;172:625-46
   PubMed Web of Science ®Google Scholar
• Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S42-80
   PubMed Web of Science ®Google Scholar
• Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-9
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Macdonald R, Ouellette J, et al. Pharmacologic therapy for primary restless legs syndrome: a systematic review and meta-analysis. JAMA Intern Med 2013;173:496-505
   PubMed Web of Science ®Google Scholar
• Rye DB, Trotti LM. Restless legs syndrome and periodic leg movements of sleep. Neurol Clin 2012;30:1137-66
   PubMed Web of Science ®Google Scholar
• Hogl B, Oertel WH, Schollmayer E, Bauer L. Transdermal rotigotine for the perioperative management of restless legs syndrome. BMC Neurol 2012;12:106
   PubMed Web of Science ®Google Scholar
• Baumann CR, Marti I, Bassetti CL. Restless legs symptoms without periodic limb movements in sleep and without response to dopaminergic agents: a restless legs-like syndrome? Eur J Neurol 2007;14:1369-72
   PubMed Web of Science ®Google Scholar
• Chotinaiwattarakul W, Dayalu P, Chervin RD, Albin RL. Risk of sleep-disordered breathing in Parkinson's disease. Sleep Breath 2011;15:471-8
   PubMed Web of Science ®Google Scholar
• Breen DP, Williams-Gray CH, Mason SL, et al. Excessive daytime sleepiness and its risk factors in incident Parkinson's disease. J Neurol Neurosurg Psychiatr 2013;84:233-4
   PubMed Web of Science ®Google Scholar
• Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive daytime sleepiness in patients with Parkinson's disease. CNS Drugs 2011;25:203-12
   PubMed Web of Science ®Google Scholar
• Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 1999;14:922-7
   PubMed Web of Science ®Google Scholar
• Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004;61:97-102
   PubMed Web of Science ®Google Scholar
• O'Suilleabhain PE, Dewey RB Jr. Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease. Arch Neurol 2002;59:986-9
   PubMed Web of Science ®Google Scholar
• Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-10
   PubMed Web of Science ®Google Scholar
• Frucht SJ. Movement disorder emergencies in the perioperative period. Neurol Clin 2004;22:379-87
   PubMed Web of Science ®Google Scholar
• Paus S, Brecht HM, Koster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003;18:659-67
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR. The dopaminergic basis of sleep dysfunction and non motor symptoms of Parkinson's disease: evidence from functional imaging. Exp Neurol 2009;216:247-8
   PubMed Web of Science ®Google Scholar
• Grinberg LT, Rueb U, Alho AT, Heinsen H. Brainstem pathology and non-motor symptoms in PD. J Neurol Sci 2010;289:81-8
   PubMed Web of Science ®Google Scholar
• Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 2007;11:113-33
   PubMed Web of Science ®Google Scholar
• Lu J, Jhou TC, Saper CB. Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J Neurosci 2006;26:193-202
   PubMed Web of Science ®Google Scholar
• Dzirasa K, Ribeiro S, Costa R, et al. Dopaminergic control of sleep-wake states. J Neurosci 2006;26:10577-89
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211
   PubMed Web of Science ®Google Scholar
• Suzuki K, Miyamoto M, Miyamoto T, et al. Sleep disturbances associated with Parkinson's disease. Parkinson's Dis 2011;2011:219056
   PubMed Web of Science ®Google Scholar
• Swick TJ. Parkinson's disease and sleep/wake disturbances. Parkinson's Dis 2012;2012:205471
   PubMed Web of Science ®Google Scholar
• Happe S, Baier PC, Helmschmied K, et al. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease. J Neurol 2007;254:1037-43
   PubMed Web of Science ®Google Scholar
• Espana RA, Scammell TE. Sleep neurobiology from a clinical perspective. Sleep 2011;34:845-58
   PubMed Web of Science ®Google Scholar
• Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011;63:182-217
   PubMed Web of Science ®Google Scholar
• Iranzo A, Lomena F, Stockner H, et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol 2010;9:1070-7
   PubMed Web of Science ®Google Scholar
• Eisensehr I, Wetter TC, Linke R, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001;57:1307-9
   PubMed Web of Science ®Google Scholar
• Witkovsky P. Dopamine and retinal function. Doc Ophthalmol 2004;108:17-40
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Liu C, Kasamatsu M, et al. Dopamine regulates melanopsin mRNA expression in intrinsically photosensitive retinal ganglion cells. Eur J Neurosci 2005;22:3129-36
   PubMed Web of Science ®Google Scholar
• Eisensehr I, Linke R, Tatsch K, et al. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. Sleep 2003;26:507-12
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Abe K, et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 2009;73:1584-91
   PubMed Web of Science ®Google Scholar
• Scheller D, Ullmer C, Berkels R, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 2009;379:73-86
   PubMed Web of Science ®Google Scholar
• Braun M, Cawello W, Poole K, Horstmann R. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease [abstract P1245]. Eur J Neurol 2005;12(Suppl 2):96
   Google Scholar
• Elshoff JP, Braun M, Andreas JO, et al. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 2012;34:966-78
   PubMed Web of Science ®Google Scholar
• Kehr J, Hu XJ, Goiny M, Scheller DK. Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. J Neural Transm 2007;114:1027-31
   PubMed Web of Science ®Google Scholar
• Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22:2398-404
   PubMed Web of Science ®Google Scholar
• Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007;64:676-82
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008;359:2468-76
   PubMed Web of Science ®Google Scholar
• Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6:513-20
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Boroojerdi B, Surmann E, Poewe W. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. J Neural Transm 2012;120:1069-81
   PubMed Web of Science ®Google Scholar
• Boroojerdi B, Wolff HM, Braun M, Scheller DK. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome. Drugs Today (Barc) 2010;46:483-505
   PubMed Web of Science ®Google Scholar
• Chen JJ, Swope DM, Dashtipour K, Lyons KE. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. Pharmacotherapy 2009;29:1452-67
   PubMed Web of Science ®Google Scholar
• Pham DQ, Nogid A. Rotigotine transdermal system for the treatment of Parkinson's disease. Clin Ther 2008;30:813-24
   PubMed Web of Science ®Google Scholar
• Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson's disease. Expert Opin Pharmacother 2009;10:677-91
   PubMed Web of Science ®Google Scholar
• Scheller D, Durmuller N, Moser P, Porsolt RD. Continuous stimulation of dopaminergic receptors by rotigotine does not interfere with the sleep-wake cycle in the rat. Eur J Pharmacol 2008;584:111-17
   PubMed Web of Science ®Google Scholar
• Giladi N, Fichtner A, Poewe W, Boroojerdi B. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease. J Neural Transm 2010;117:1395-9
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26:90-9
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord 2013;19:660-5
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Surmann E, Boroojerdi B, et al. Association between motor and nonmotor symptoms in patients with Parkinson's Disease (PD): a post hoc analysis of the randomized evaluation of the 24-h coverage: efficacy of rotigotine (RECOVER) study. Mov Disord 2011;26(Suppl 2):S127
   Google Scholar
• Perez-Lloret S, Rey MV, Ratti PL, Rascol O. Rotigotine transdermal patch for the treatment of Parkinson's Disease. Fundam Clin Pharmacol 2013;27:81-95
   PubMed Web of Science ®Google Scholar
• Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5
   PubMed Web of Science ®Google Scholar
• Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep 1992;15:376-81
   PubMed Web of Science ®Google Scholar
• Elmer LW, Surmann E, Boroojerdi B, Jankovic J. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord 2012;18:488-93
   PubMed Web of Science ®Google Scholar
• Antonini A, Albin RL. Dopaminergic treatment and nonmotor features of Parkinson disease: the horse lives. Neurology 2013;80:784-5
   PubMed Web of Science ®Google Scholar
• Pilleri M, Koutsikos K, Antonini A. Is there room for new non-dopaminergic treatments in Parkinson's disease? J Neural Transm 2012;120:349-52
   PubMedGoogle Scholar
• Postuma RB, Gagnon JF, Vendette M, et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009;72:1296-300
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003;60:1721-8
   PubMed Web of Science ®Google Scholar
• Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68(4):272-6
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R; for SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007;68(16):1262-7
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;73:629-35
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kohnen R, Hogl B, et al. Parkinson's disease sleep scale–validation of the revised version PDSS-2. Mov Disord 2011;26:644-52
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213
   PubMed Web of Science ®Google Scholar